Business news

Belarus’ NatiVita to produce lung cancer vaccine using Cuban solutions

Photo courtesy of the NatiVita

MINSK, 14 February (BelTA) – Belarus’ NatiVita and Cuba’s Center of Molecular Immunology (CIM) have signed an agreement on the transfer of technology for full-cycle production and quality control of a vaccine to treat lung cancer CIMAvax-EGF, BelTA learned from the company.

CIMAvax-EGF is specifically used to treat locally advanced or metastatic non-small-cell lung carcinoma (NSCLC) (stages IIIB-IV). According to statistics, lung cancer is one of the most common causes of cancer death. Non-small-cell lung carcinoma morbidity rate is 29.12 people per 1000,000 population; 41% of them are patients with the stages III-IV. One of the advantages of this vaccine is a possibility to combine it with standard chemotherapy during the supporting therapy after all treatment options are over. The vaccine helps significantly prolong the life of patients and improve the quality of life. Clinical trials suggest that the five-year survival rate of vaccinated patients with a non-small-cell lung carcinoma is 16.6% vs. 6.2% in patients who did not receive the vaccine.

The company noted that the agreement is the first stage of cooperation to develop and market innovative medicines to treat grave diseases. As part of a cooperation project with BioCubaFarma, the Cuban organization of Biotechnology and Pharmaceutical Industries, the Belarusian company will soon release several innovative medications on the Belarusian market.

The project became possible due to the support of the Belarusian Embassy in Cuba and BioCubaFarma.

print version

make home page

add to bookmarks